Sanofi alerts patients and clinicians as supplies of two Pompe disease medicines dwindle
Sanofi has notified clinicians and patient groups that supplies of Myozyme and Nexviazyme for Pompe disease are dwindling due to bottlenecks and quality-control issues at its Waterford, Ireland, manufacturing site, which handles batch release for multiple markets.
